A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern.

Bárbara M Schultz^{1,#}, Felipe Melo-González^{1,#}, Luisa F Duarte^{1,#}, Nicolás MS 4 Gálvez^{1,#}, Gaspar A Pacheco^{1,#}, Jorge A Soto^{1,#}, Roslye V Berríos-Rojas^{1,2}, Liliana 5 A González^{1,2}, Daniela Moreno-Tapia^{1,2}, Daniela Rivera-Pérez^{1,2}, Mariana Ríos^{1,2}, 6 Yaneisi Vázguez^{1,2}, Guillermo Hoppe-Elsholz^{1,2}, Omar P Vallejos^{1,2}, Carolina 7 Iturriaga³, Marcela Urzua³, María S Navarrete⁴, Álvaro Rojas⁴, Rodrigo Fasce⁵, 8 9 Jorge Fernández⁵, Judith Mora⁵, Eugenio Ramírez⁵, Aracelly Gaete-Argel^{1,6}, Mónica Acevedo^{1,6}, Fernando Valiente-Echeverría^{1,6}, Ricardo Soto-Rifo^{1,6}, Daniela 10 11 Weiskopf⁷, Alba Grifoni⁷, Alessandro Sette^{7,8}, Gang Zeng⁹, Weining Meng⁹, CoronaVac03CL Study Group, José V González-Aramundiz¹⁰, Pablo A 12 13 González^{1,2}, Katia Abarca^{1,3}, Alexis M Kalergis^{*1,2,11}, Susan M Bueno^{*1,2}

14

15 **Affiliations:**

16 ¹Millennium Institute on Immunology and Immunotherapy, Santiago, Chile. 17 ²Departamento de Genética Molecular y Microbiología, Facultad de Ciencias 18 Biológicas, Pontificia Universidad Católica Chile, de Santiago, Chile. 19 ³Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, División 20 de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, 21 Santiago, Chile. ⁴Departamento de Enfermedades Infecciosas del Adulto, División 22 de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile, 23 Santiago, Chile. ⁵Departamento de Laboratorio Biomédico, Instituto de Salud

24	Pública de Chile. ⁶ Laboratorio de Virología Molecular y Celular, Programa de
25	Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de
26	Chile, Santiago, Chile. ⁷ Center for Infectious Disease and Vaccine Research, La
27	Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. 8Department of
28	Medicine, Division of Infectious Diseases and Global Public Health, University of
29	California, San Diego (UCSD), La Jolla, CA 92037, USA. ⁹ Sinovac Biotech, Beijing,
30	China. ¹⁰ Departamento de Farmacia, Facultad de Química y de Farmacia,
31	Pontificia Universidad Católica de Chile, Santiago, Chile. ¹¹ Departamento de
32	Endocrinología, Facultad de Medicina, Escuela de Medicina, Pontificia Universidad
33	Católica de Chile, Santiago, Chile.
34	

35 [#] These authors contributed equally to this work.

36

37 *Corresponding authors.

38 Keywords:

39 CoronaVac; Phase 3 clinical trial; SARS-CoV-2; COVID-19; inactivated vaccine,

40 Booster dose.

41

42 Abstract

Background: CoronaVac[®] is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization. Previous studies reported increased levels of neutralizing antibodies and specific T cells two- and four-weeks after two doses of CoronaVac[®], but the levels of neutralizing antibodies are reduced at six to eight months after two doses. Here we report the effect of a booster dose of CoronaVac[®] on the anti-SARS-CoV-2 immune response generated against variants of concern (VOC) Delta and Omicron in adults participating in a phase 3 clinical trial in Chile.

Methods: Volunteers immunized with two doses of CoronaVac[®] in a four-week 50 interval received a booster dose of the same vaccine between twenty-four and 51 52 thirty weeks after the 2nd dose. Four weeks after the booster dose, neutralizing 53 antibodies and T cell responses were measured. Neutralization capacities and T 54 cell activation against VOC Delta and Omicron were detected at four weeks after 55 the booster dose. Findings: We observed a significant increase in neutralizing 56 antibodies at four weeks after the booster dose. We also observed an increase in CD4⁺ T cells numbers over time, reaching a peak at four weeks after the booster 57 dose. Furthermore, neutralizing antibodies and SARS-CoV-2 specific T cells 58 induced by the booster showed activity against VOC Delta and Omicron. 59 Interpretation: Our results show that a booster dose of CoronaVac[®] increases the 60 anti-SARS-CoV-2 humoral and cellular immune responses in adults. Immunity 61 induced by a booster dose of CoronaVac[®] is active against VOC, suggesting an 62 63 effective protection.

64

65 Background

66 The ongoing pandemic caused by severe acute respiratory syndrome 67 coronavirus-2 (SARS-CoV-2) has promoted the rapid development of safe, 68 immunogenic, and effective vaccines against SARS-CoV-2 to be used by the 69 general population, which have successfully reduced the transmission of the 70 disease burden. CoronaVac[®] is an inactivated SARS-CoV-2 vaccine developed by 71 Sinovac Life Sciences Co., Ltd. (Beijing, China) and is among the current vaccines 72 approved by the World Health Organization (WHO) to combat coronavirus disease 73 2019 (COVID-19) and one of the most used vaccines worldwide^{1,2}. Phase I/II 74 clinical trials in China demonstrated that this vaccine induces cellular and humoral response upon immunization ^{3–5}. Furthermore, the ongoing phase 3 clinical trial in 75 Chile has described an increase in the levels of IgG and neutralizing antibodies in 76 77 adults aged 18-59 years and \geq 60 years two- and four-weeks after the second dose of CoronaVac^{® 56}. In addition, this vaccination promotes the activation of a T cell 78 immune response against SARS-CoV-2 antigens in a 0-14 immunization schedule 79 ⁵ (two-weeks interval), being an effective vaccine to prevent COVID-19^{7,8}. In Chile, 80 81 93.7% of the target population has received a first vaccine dose, and 91.4% were fully vaccinated with CoronaVac® on December 10th of 2021 in a 0-28 days 82 83 vaccination schedule ⁹. Although this primary immunization schedule induces 84 neutralizing antibody present in the serum of vaccinated people ¹⁰, these titers decrease in time ^{6,11,12} and have lower levels of neutralization against highly 85 86 transmissible variants of concern (VOC) as compared to the original vaccine strain, 87 potentially decreasing the effectiveness of these vaccines as new variants emerge

88 ^{13–17}. For these reasons, the use of booster doses was approved in Chile in August 89 2021 in Chile for high-risk populations and adults at five months after 90 administration of the second dose ¹⁸. In this sense, a report published in October 2021 in Chile, showed that the effectiveness of CoronaVac[®] against COVID-19 91 92 increase from 56% to 80% fourteen days after the application of the booster dose 93 ¹⁹. Notably, a previous study performed in adults aged 18-59 years old 94 demonstrated that a booster dose of CoronaVac[®], applied six months after the first 95 dose to individuals that previously received two doses of this vaccine, increased the levels of antibodies 3-5-fold as compared to the levels observed four weeks 96 after the second dose ¹². Here, we further extend these findings by reporting the 97 98 levels of neutralizing antibodies and specific T cells against SARS-CoV-2 and its 99 activity against VOC Delta and Omicron in adults ≥18 years old that participated in 100 the phase 3 clinical trial carried out in Chile, who were vaccinated in a 0-28-days 101 vaccination schedule and received a booster dose five months after the second 102 dose.

103

104 Materials and methods

105 Volunteers and sample collection

Blood samples were obtained from volunteers recruited in the clinical trial CoronaVac03CL (clinicaltrials.gov #NCT04651790) carried out in Chile starting in November 2020. The Institutional Scientific Ethical Committee of Health Sciences reviewed and approved the study protocol at the Pontificia Universidad Católica de Chile (#200708006). Trial execution was approved by the Chilean Public Health Institute (#24204/20) and was conducted according to the current Tripartite

Guidelines for Good Clinical Practices, the Declaration of Helsinki²⁰, and local 112 113 regulations. Informed consent was obtained from all volunteers upon enrollment. Volunteers receive two doses of CoronaVac[®] (3 µg or 600SU of inactivated SARS-114 115 CoV-2 inactivated along with alum adjuvant) in a four-week interval (0-28-day 116 immunization schedule) and then a booster dose five months after the second 117 dose. A complete inclusion and exclusion criteria list have been reported ⁵. On 118 November 11th, 2021, one hundred and eighty-six volunteers in the immunogenicity 119 branch received the booster dose. The antibody and cell mediated immune responses were evaluated volunteers that had completed all their previous visits in 120 121 one of the centers of the study (Figure 1A). Blood samples were obtained from all 122 the volunteers before administration of the first dose (pre-immune), two, four, and 123 twenty weeks (or five months) after the second dose, and four weeks after the 124 booster dose (Figure 1B).

125 **Procedures**

126 The presence of antibodies against RBD with neutralizing capacities were 127 measured in sera from seventy-seven volunteers that had completed all their study 128 visits, including one month after the booster dose of CoronaVac[®]. The neutralizing capacities of circulating antibodies were evaluated by a surrogate virus 129 130 neutralization test (sVNT) (Genscript Cat#L00847-A). Samples were two-fold serially diluted starting at a 4-fold dilution until reaching a 512-fold dilution. Assays 131 132 were performed according to the instructions of the manufacturer and as reported 133 previously ⁵. Neutralizing antibody titers were determined as the last fold dilution in which the interaction between hACE2 and RBD was inhibited by 30% or more. 134 135 Samples with a percentage of inhibition $\leq 30\%$ at the lowest dilution (1:4) were

136 assigned as seronegative with a titer of 2. A sample was considered seropositive 137 when its titer was higher than the pre-immune titer. The percentage of inhibition 138 was determined as: 100 * [OD450nm value of negative control - OD450nm value of 139 sample] / [OD450nm of negative control]. A standard curve was used to plot the 140 neutralization response in the samples as international units (IU) using the WHO 141 International Standard for SARS-CoV-2 antibody (NIBSC code 20/136), which was prepared according to the instructions of the manufacturer ²¹. Data were analyzed 142 143 using a sigmoidal curve model with a logarithm transformation of the concentration, 144 and the final concentration for each sample was the average of the product of the 145 interpolated IU from the standard curve and the sample dilution factor required to 146 reach the OD450 value that falls within the linear range determined for each 147 sample. Samples with undetermined concentration at the lowest dilution tested 148 (1:4) were assigned to the lower limit of quantification (16.4 IU). The Geometric 149 Mean Units (GMU) and titers (GMT) were represented in Figure 2 and 150 Supplementary Figure 1, respectively. Table 2 shows comparisons among the 151 visits.

152 Conventional virus neutralization tests (cVNT) were performed in sixty-two 153 of the previous seventy-seven volunteers and evaluated as previously reported ⁵. 154 Briefly, Vero E6 cells were infected with a SARS-CoV-2 strain obtained by viral 155 isolation in tissue cultures (33782CL-SARS-CoV-2 strain, D614G variant). 156 Neutralization assays were carried out by the reduction of cytopathic effect (CPE) 157 in Vero E6 cells (ATCC CRL-1586). The titer of neutralizing antibodies was defined 158 as the highest serum dilution that neutralized virus infection, at which the CPE was 159 absent as compared with the virus control wells (cells with CPE). Vero E6 cells were seeded in 96-well plates (4×10^4 cells/well). For neutralization assays, 100 µL of 33782CL-SARS-CoV-2 (at a dose of 100 TCID₅₀) were incubated with serial dilutions of heat-inactivated sera samples (dilutions of 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:256, and 1:512) from participants for 1h at 37 °C. Cytopathic effect on Vero E6 cells was analyzed 7 days after infection.

165 A pseudotyped virus neutralization test (pVNT) assay was performed to 166 assess the capacity of the antibodies against SARS-CoV-2 VOC in samples from 167 thirty volunteers of the seventy-seven previously analyzed by sVNT. As previously 168 reported ¹⁴, a HIV-1 backbone expressing firefly luciferase as a reporter gene and 169 pseudotyped with the SARS-CoV-2 spike glycoproteins (HIV-1-S Δ 19) from from 170 lineage B.1 (D614G) or variants Delta (T19R, del157/158, L452R, T478K, D614G, 171 P681R, D950N) and Omicron (A67V, AH69-V70, T95I, Y145D, AG142 -V143-172 Y144, △N211, EPE 213-214, G339D, S371L, S373P, S375F, K417N, N440K, 173 G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, T547K, D614G, 174 H655Y, N679K, P681H, N764K, N865K, Q954H, N969K, L981F) was prepared as 175 previously described ²². Serum samples were two-fold diluted starting at 1:10 or 1:4 176 and the estimation of the ID80 was obtained using a 4-parameter nonlinear 177 regression curve fit measured as the percent of neutralization determined by the 178 difference in average relative light units (RLU) between test samples and 179 pseudotyped virus controls. Also, cVNT assays were performed to assess the 180 capacity of the antibodies against SARS-CoV-2 Delta variant in samples from 181 nineteen volunteers of the seventy-seven previously analyzed by sVNT.

182 ELISPOT and flow cytometry assays were performed to evaluate the cellular 183 immune response in forty volunteers of the seventy-seven previously analyzed

184 (Figure 1A), stimulating PBMCs with four Mega Pools (MPs) of peptides derived from the proteome of SARS-CoV-2²³: peptides from the S protein of SARS-CoV-2 185 186 (MP-S), the remaining proteins of the viral particle (excluding S protein peptides) 187 (MP-R), and shorter peptides from the whole proteome of SARS-CoV-2 (MP-CD8-188 A and MP-CD8-B)²³. Thirty of the previously analyzed volunteers were also 189 stimulated with three Mega Pools (MP) of VOC, provided by La Jolla Institute for 190 Immunology. MP derived from the S protein of SARS-CoV-2 WT, SARS-CoV-2 191 B1.617.2 MP 4326 (Delta variant), and SARS-CoV-2 B1.1.529 MP 4359 (Omicron 192 variant) ¹⁴ were used to evaluate T cell activation at four weeks after the booster 193 dose. Positive and negative controls were held for each assay. The number of Spot 194 Forming Cells (SFC) for interferon gamma (IFN- γ) were determined by ELISPOT and the expression of Activation-Induced Markers (AIM) by T cells was evaluated 195 196 by flow cytometry. Assays were performed according to the instructions of the manufacturer and as reported previously ⁵. Further details on the ELISPOT assay, 197 198 antibodies used for flow cytometry, and the respective protocols can be found in 199 the Supplementary information and **Supplementary Table 1**.

Interleukin 2 (IL-2) and IFN-γ secretion were evaluated in the supernatants of twenty-two volunteers previously stimulated for 20h with SARS-CoV-2 MP of peptides derived from the Spike protein of VOC, using a Luminex 200 xMap multiplex system (Luminex Corporation, Austin, TX). The limit of detection for the cytokine measured ranged from 4.2 to 13,390 pg/mL, according to manufacturer's instructions. Further experimental details can be found in **Supplementary Information**.

207

208 Statistical analyses

209 Statistical differences for the immunogenicity results considered repeated 210 measures ANOVA with the Geisser-Greenhouse correction and Dunnet's a 211 *posteriori* multiple tests to compare between the booster dose and the other visits. 212 Analyses were performed over the base 10 logarithms of the data for neutralizing 213 antibody by sVNT, cVNT and pVNT. Cellular immune responses were analyzed by 214 a Friedman test for repeated measures for ELISPOT and flow cytometry for the 215 comparisons between booster dose and the other visits. Secretion of cytokines 216 were compared between the secretion induced by the WT strain against the VOC 217 Delta and Omicron by repeated measures ANOVA. The significance level was set 218 at 0.05 for all the analyses. All data were analyzed with GraphPad Prism 9.0.1.

219

220 Results

A booster dose of CoronaVac[®] induces a significant increase in antibody titers with neutralizing capacity in adults.

223 One hundred and eighty-six volunteers from the immunogenicity branch that 224 received a booster dose of the CoronaVac[®] were included in this study. The first 225 dose of the vaccine was inoculated from January to March of 2021, and the second 226 dose was inoculated 28 days after the first one. The neutralizing capacity of serum 227 antibodies was evaluated in seventy-seven and sixty-two volunteers by sVNT and 228 cVNT, respectively, at the five different time-points indicated in **Figure 1B**.

As shown in **Figures 2A and D**, the peak level of antibodies with neutralizing capacity in the total population evaluated, tested by sVNT and cVNT, 231 is reached at two weeks after the second dose (GMU 168.0, 95% CI=19.5-34.2 232 and GMT, 95% CI=) and four weeks after the second dose (GMU 124.8, 95% 233 CI=96.3-161.7 and GMT 13.5, 95% CI=9.6-19.2). However, this neutralizing 234 capacity significantly decreased twenty weeks after the second dose (GMU 39.0. 235 95% CI=32.4-47.0 and GMT 8.3, 95% CI=9.6-19.2), which is in line with previous 236 reports where the immunity against SARS-CoV-2 wanes six months after infection or vaccination ^{24,25}. After the booster dose, the neutralizing capacity of the 237 238 antibodies increased even more than the one reported two weeks after the second 239 dose (GMU 499.0, 95% CI=370.6-673.0 and GMT 89.5 ± 64.0-125.2). Overall, we 240 observed that four weeks after the booster dose the neutralizing capacity increased 241 more than 12-fold (sVNT) and 10-fold (cVNT) as compared to the response at 242 twenty weeks after the second dose, and almost 3-fold as compared to two weeks 243 after the second dose (Figures 2A and D).

244 In adults 18-59 years old, the neutralizing capacity of circulating antibodies 245 tested by sVNT and cVNT (Figures 2B and E, respectively) reached its maximum 246 four weeks after the booster dose (GMU 918.8, 95% CI=623.4-1354 and 176.9, 247 95% CI=111.7-280.1) increasing more than 18- and 12-fold as compared to five 248 months after the second dose (GMU 48.9, 95% CI=37.6-63.5 and GMT 14.2, 95% 249 CI=7.1-28.4) and more than 4-fold as compared to two weeks after the second 250 dose (GMU 220.2, 95% CI=150.7-321.7 and GMT 17.5, 95% CI=9.8-31.3) 251 (Figures 2B and E). The seropositivity rate in this group reached 100% at four 252 weeks after the booster dose (Table 2). On the other hand, 53.2% of the total 253 volunteers analyzed here were adults ≥ 60 years. In this group, the same tendency

254 was observed, as seen in Figure 2C and F, observing an increase in the level of 255 neutralizing antibodies evaluated by both techniques of more than 9-fold at four 256 weeks after the booster dose (GMU 300.5, 95% CI=203.5-443.6 and GMT 47.3, 257 95% CI=32.1-69.5) as compared to the response observed twenty weeks after the 258 second dose (GMU 32.4, 95% CI=25.1-41.8 and GMT 5.0, 95% CI=3.5-7.0). 259 Equivalent to the 18-59 years old group, the seropositivity rate in this age group 260 reached 100% four weeks after the booster dose (**Table 2**). The seropositivity rate 261 achieved at four weeks after the booster dose was the highest when compared 262 with the other visits in this study in the total vaccinated group and in both groups 263 analyzed.

264

A booster dose of CoronaVac[®] induces a robust cellular immune
 response in adults.

The cellular responses following a booster dose of CoronaVac[®] were 267 268 evaluated in 40 volunteers. We observed that CD4⁺ T cell activation was increased 269 twenty weeks after the second dose as compared to the other time points in both 270 age groups, suggesting that CoronaVac® can stimulate CD4⁺ T cell responses that 271 are sustained over time (Figure 3A-C). Importantly, we observed a significantly 272 further increase in CD4⁺ T cell activation in both age groups following the booster dose, as compared to the pre-immune sample and samples obtained at two and 273 274 four weeks after the second dose (Figure 3A-C). However, this difference was not 275 significant as compared to the sample obtained twenty weeks after the second 276 dose (Figure 3A-C). Moreover, we did not observe a significant increase in the 277 expression of AIM by CD8⁺ T cells following the booster dose as compared to any

278 other time point, suggesting that specific CD8⁺ T cell responses induced by 279 CoronaVac[®] are not detected with the current methodologies, even after a third dose (Supp. Figure 2A and C). Accordingly, we observed an increase in IFN- γ 280 production upon stimulation with mega-pools of peptides (MPs) S and R by 281 282 ELISPOT at four weeks after the booster dose for both groups, as compared to the 283 pre-immune sample (Figure 3D-F). As in the case of flow cytometry, we did not observe significant increase of IFN-γ⁺ SFCs upon stimulation with CD8 MPs at any 284 285 time point (Supp. Figure 2). These results suggest that although humoral 286 responses decrease over time following vaccination with CoronaVac[®], CD4⁺ T cell 287 responses remain significantly increased as compared to pre-immune samples and the booster dose promotes a small increase both IFN-y production and CD4⁺ T cell 288 289 activation that is not significantly different as compared to the levels observed 20 290 weeks after the second dose.

291

292 Neutralizing antibodies and specific T cells induced by a booster dose 293 of CoronaVac® recognize Delta and Omicron variants of SARS-CoV-2.

As we observed that the neutralization capacity and the T cell responses increased significantly with the booster dose and knowing that vaccinated volunteers exhibit decreased neutralization against VOC¹⁴, we proceeded to evaluate the neutralizing capacities of antibodies in the serum from thirty boostervaccinated individuals in pseudotyped virus neutralization test (pVNT) assay against two variants of concern of SARS-CoV-2, comparing with the level obtained for the D614G SARS-CoV-2 variant (B.1 lineage, **Figure 4A-B**). We observed that

301 the titers of antibodies with neutralizing capacities against Delta and Omicron 302 variant show a significant reduction as compared to the levels achieved for the 303 D61G variant (D614G: GMT 241.8, CI=155.7-375.6, Delta: 159.2, CI=99.1-256.0 304 and Omicron: GMT 50.7. CI=30.4-84.8), with a reduction of 1.5 for Delta and 4.8 305 for Omicron (Figure 4A). However, when we compared the changes in 306 seropositivity for Delta and Omicron (Figure 4B), we observed a 93% and 76.7%, 307 respectively, following the booster dose (**Table 3**). Neutralization assays against 308 Delta variant with a cVNT in a different group of nineteen volunteers also show that 309 antibodies induced four weeks after the booster dose have reduced capacity to 310 neutralize this VOC (**Supp Figure 4A**), although the seropositivity rate observed is 311 84% (Supp Figure 4B).

312 The cellular responses for VOC following a booster dose of CoronaVac® 313 were also evaluated in thirty volunteers using MPs of peptides derived from the 314 Spike protein of Delta and Omicron variants. We observed equivalent numbers of 315 AIM by CD4⁺T cells after four weeks of the booster dose upon stimulation with MP-316 S of SARS-CoV-2 WT, Delta, or Omicron variant (Figure 5A), with no significant 317 differences between the response against the MP-S of the variants as compared to 318 the MP-S of the WT strain. IFN- γ secreting T cells were also analyzed in these 319 samples and no differences were observed (Figure 5B). We also quantified the 320 production of different cytokines in the supernatant of PBMCs stimulated with the 321 MP-s of WT, Delta, and Omicron variants, observing that at four weeks after the 322 booster dose the stimulated cells secrete equivalent levels of IL-2 and IFN-y 323 (Figure Supp 3). These results suggest that although the humoral response

measured as neutralization capacities and seroconversion against these VOC is lower as compared to the humoral response against the D614G strain, the cellular responses against SARS-CoV-2 VOC is equivalent to the responses elicited by the wild type strain in volunteers vaccinated with booster dose.

328

329 Discussion

In this report we evaluated the humoral and cellular immune response 330 331 generated four weeks after the application of a booster dose of inactivated 332 CoronaVac® vaccine in a cohort of volunteers enrolled in the phase 3 clinical trial 333 held in Chile. The data reported here showed that although there was an adequate humoral response after two doses of CoronaVac[®], with a 65.9% of effectiveness in 334 335 preventing COVID-19⁸, both the sVNT and cVNT assays showed a decrease in 336 the GMT of neutralizing capacities of circulating antibodies against SARS-CoV2 337 twenty weeks after the second dose (Figure 2). Due to this decrease in neutralizing capacities, a booster dose of CoronaVac[®] was evaluated in a clinical 338 339 study in China, showing promising results in enhanced humoral immune responses^{12,26}. The evaluation of the immune response reported here shows that 340 341 after the booster dose, the neutralizing titers and seroconversion rates increase in 342 the whole group, to a higher extent than two weeks after the second dose, where the peak in neutralization was previously observed, which is in line with the 343 observed by Clemens et al.,¹⁵. Also, we observed a steady activation of the CD4⁺ 344 345 T cells and secretion of IFN- γ during the time-points evaluated (**Figure 3**).

346 Since the neutralizing antibody titers correlated with protection against 347 SARS-CoV-2 infection ¹⁰, these results likely imply a better outcome and protection 348 against COVID-19, as reported in previous studies performed in Israel that showed 349 a decrease in the transmission and the disease severity disease by this virus 350 twelve or more days after booster inoculation. In Chile, the effectiveness and 351 prevention in hospitalization increased when assessed fourteen days after the booster dose of CoronaVac^{® 19,27}. Another study, performed with a booster dose of 352 353 CoronaVac[®], showed that an additional dose result in good neutralization capacity 354 against parental SARS-CoV-2 and against Delta variant four weeks after the 355 booster dose, generating a long-lasting humoral response, which was due to an enhancement of the memory immune response generated by B cells ²⁶. 356

357 Adults ≥60 years old produced lower levels of antibodies with neutralizing 358 capacities than the whole group during this study, which was also described 359 previously (Figure 2C and F)⁵. This result is in line with previous data reported for a population vaccinated in Chile⁶, among hospital workers who received two 360 doses of CoronaVac^{® 28}, and in a study with the mRNA-1273 vaccine ²⁹. In this 361 362 sense, our results are equivalent to those described in a phase I/II of the clinical trial performed with CoronaVac[®] in China, showing that the neutralizing antibody 363 364 titers in this group decreased at five months after the second dose and that a 365 booster dose is required 6-8 months after the first vaccination to rapidly increase 366 and maintain the neutralizing antibody titers 30 .

In the case of the T cell response (**Figure 3**), other studies have shown that Pfizer BNT162b2 and mRNA-1273 induce durable CD4⁺ T cell activation and cytokine production up to six months following vaccination, but it remains to be 370 elucidated whether expression of AIM by CD4⁺ T cells and cytokine production 371 further increase following a booster dose with these vaccines ^{31,32}. Here, we observed that the activation of CD4⁺ T cells and IFN- γ production stays increased 372 up to twenty weeks after the second dose, and after the booster dose both 373 374 parameters increased in the 18-59 years old group and was maintained at the 375 levels observed twenty weeks after the second dose in adults ≥60 years old. In contrast to BNT162b2 and mRNA-1273 vaccines, CoronaVac® delivers not only 376 377 the Spike protein upon immunization but also other viral antigens, which may 378 explain why vaccinated individuals still display AIM⁺ CD4⁺ T cells five months after 379 the second dose, regardless of a third dose.

When the neutralization capacity analyzed by pVNT of the VOC Delta and 380 381 Omicron was evaluated four weeks after the booster dose, we observed differences in the neutralization capacity as compared to the D614G variant 382 383 (lineage B.1), which does not exhibit mutations in the RBD of the S1 protein 384 (Figure 4 and table 3). We previously reported that CoronaVac[®] is able to induce 385 neutralization against the Delta variant at 4 weeks after the second dose, although 386 to a lesser extent compared to the WT strain ¹⁴. Another study recently reported a 387 significant increase in the neutralizing capacity after a booster dose with 388 CoronaVac[®] for the Delta variant, as compared to the levels observed in volunteers 389 vaccinated with two doses ^{26,33}. Although we did not observe similar levels of 390 enhanced neutralization against the variants Delta after the booster dose using 391 pVNT (Figure 4A), the seropositivity against Delta variant is almost 100% (Figure 392 **4B**)³³. Here, we also show that a booster dose induces neutralization against the

393 variant Omicron, which has rapidly spread worldwide and is the predominant 394 circulating variant to date ³⁴. The high number of mutations described in the RBD of 395 this variant has been associated with increased evasion of neutralizing responses 396 in either unvaccinated or vaccinated subjects ^{34,35}. Although the neutralization 397 observed in subjects vaccinated with a booster dose of CoronaVac[®] is significantly 398 lower to the observed against the D614G variant, we observed a seropositivity of 399 76.7% following the booster, suggesting some degree of protection in most of the 400 vaccinees. In this sense, it has been reported that a heterologous schedule of vaccination may induce a higher neutralization ability and a better neutralization 401 against variants of concern as Delta ³⁶ and Omicron¹⁶. In line with this, a 402 heterologous vaccination with CoronaVac[®] and a booster dose of Pfizer BNT162b2 403 showed a good neutralization titer against VOC Delta and Omicron, with respect to 404 405 the ancestral virus ¹⁶. Similarly, a comparison between heterologous and homologous booster schedules after the vaccination with CoronaVac[®], shows an 406 407 increase in neutralization against the VOC Delta and Omicron¹⁵. There are 408 discrepancies between the results in neutralization titers, which can be attributed to 409 the neutralization assays performed and/or the study population; however, 410 important booster responses are observed in these studies, and seropositivity 411 reached after the booster dose of CoronaVac[®] against VOC are also similar ¹⁶.

In the case of the cellular response, this is the first report to characterize CD4⁺ T cell responses following a booster dose of CoronaVac[®] against the Omicron variant of SARS-CoV2. Previous studies using the same MP from VOC evaluated here have shown that CD4⁺ T cells respond to VOC in a similar extent as compared to the ancestral strain in individuals vaccinated with CoronaVac[®] ^{14,37}

417 and mRNA vaccines, which has been explained by the high conservation of T cell 418 epitopes. In this sense, the booster dose of CoronaVac[®] induces the expression of 419 CD4⁺ T cell activation markers and secretion of IFN-y and IL-2 against the VOC 420 Delta and Omicron, which is comparable to the response generated against the 421 WT strain (Figure 5). In line with this, a recent study has shown that T cell 422 responses against the ancestral strain are cross-reactive against the Omicron 423 variant in convalescent individuals and volunteers vaccinated with Pfizer 424 BNT162b2 ³⁸, supporting the idea that the induction of T cell responses against the 425 ancestral strain may be protective against the Omicron variant.

Our report shows that the booster dose of CoronaVac[®] in a 0-28 days 426 427 schedule induces antibodies with neutralizing capacities, which are higher than the 428 levels observed at 2- and 4-weeks after the second dose, generating an increased 429 humoral response even in adults ≥60 years old. Besides this, our results suggest that a third dose of CoronaVac[®] supports CD4⁺ T cell activation, which may confer 430 431 either protection or enhanced immune responses against the virus and prevent 432 severe disease following exposure to SARS-CoV-2 exposure. Importantly, the 433 humoral and cellular immune response promoted by a booster dose of CoronaVac 434 shows activity against Delta and Omicron variants and probably results in better 435 effectiveness of this vaccine during predominance of these VOC.

436

437 **Limitations**

This study presents several limitations, such as the reduced sample size forthe assays and the absence of data for neutralization against Omicron variant with

440 a conventional viral neutralization test. The assessment of total antibody response 441 against Spike proteins and other SARS-CoV-2 proteins would also add additional 442 information about the humoral immune response against SARS-CoV-2 after the 443 booster dose. Due to the limit of quantification of the technique, samples with 444 undetermined concentration at the lowest dilution tested (1:4) were assigned the 445 lower limit of quantification (16.4 IU) and other neutralization assays.

446

447 **Funding**

448 The CoronaVac03CL Study was funded by The Ministry of Health, 449 Government of Chile, the Confederation of Production and Commerce (CPC), 450 Chile and SINOVAC Biotech. NIH NIAID, under Contract 75N93021C00016, 451 supports AS and Contract 75N9301900065 supports AS, AG and DW. The 452 National Agency for Research and Development (ANID) through the Fondo 453 Nacional de Desarrollo Científico y Tecnológico (FONDECYT) grants Nº 1190156 454 and Nº 1211547 supports RSR and FVE, respectively. The Millennium Institute on 455 Immunology and Immunotherapy, ANID - Millennium Science Initiative Program 456 ICN09 016 (former P09/016-F) supports RSR, VFE, SMB, KA, PAG and AMK; The Innovation Fund for Competitiveness FIC-R 2017 (BIP Code: 30488811-0) 457 458 supports SMB, PAG and AMK.

459 **Competing interests**

460 ZG and MW are SINOVAC Biotech employees and contributed to the 461 conceptualization of the study (clinical protocol and eCRF design) and did not 462 participate in the analysis or interpretation of the data presented in the manuscript.

A.S. is a consultant for Gritstone, Flow Pharma, Arcturus, Immunoscape,
CellCarta, OxfordImmunotech and Avalia. La Jolla Institute for Immunology (LJI)
has filed for patent protection for various aspects of T cell epitope and vaccine
design work. All other authors declare no conflict of interest.

467

468 Acknowledgments

We would like to thank the support of the Ministry of Health, Government of Chile; 469 470 Ministry of Science, Technology, Knowledge, and Innovation, Government of Chile; 471 The Ministry of Foreign Affairs, Government of Chile, and the Chilean Public Health 472 Institute (ISP). We also would like to thank Rami Scharf, Jessica White, Jorge 473 Flores and Miren Iturriza-Gomara from PATH for their support on experimental 474 design and discussion. Alex Cabrera and Sergio Bustos from the Flow Cytometry 475 Facility at Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile 476 for support with flow cytometry. We also thank the Vice Presidency of Research 477 (VRI), the Direction of Technology Transfer and Development (DTD), the Legal 478 Affairs Department (DAJ) of the Pontificia Universidad Católica de Chile. We are 479 also grateful to the Administrative Directions of the School of Biological Sciences 480 and the School of Medicine of the Pontificia Universidad Católica de Chile for their 481 administrative support. We would also like to thank the members of the independent data safety monitoring committee (members in the SA) for their 482 483 oversight, and the subjects enrolled in the study for their participation and 484 commitment to this trial. This project has been funded in whole or in part with 485 Federal funds from the National Institute of Allergy and Infectious Diseases,

- 486 National Institutes of Health, Department of Health and Human Services, under
- 487 Contract No. Contract No. 75N9301900065 to A.S, A.G. and D.W.

488

- 489 Note: Members of the CoronaVac03CL Study Group are listed in the
- 490 Supplementary Appendix (SA).

491

492 **References**

- 493 1. Mallapaty S. WHO approval of Chinese CoronaVac COVID vaccine will be
- 494 crucial to curbing pandemic [Internet]. Nature. 2021 [cited 2021 Oct
- 495 6];594(7862):161–2. Available from:
- 496 https://pubmed.ncbi.nlm.nih.gov/34089030/
- 497 2. Q G, L B, H M, et al. Development of an inactivated vaccine candidate for
- 498 SARS-CoV-2. Science [Internet] 2020 [cited 2021 Oct 6];369(6499):77–81.
- 499 Available from: https://pubmed.ncbi.nlm.nih.gov/32376603/
- 500 3. Z W, Y H, M X, et al. Safety, tolerability, and immunogenicity of an
- 501 inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60
- 502 years and older: a randomised, double-blind, placebo-controlled, phase 1/2
- 503 clinical trial. Lancet Infect Dis [Internet] 2021 [cited 2021 Oct 6];21(6):803–
- 504 12. Available from: https://pubmed.ncbi.nlm.nih.gov/33548194/
- 505 4. Y Z, G Z, H P, et al. Safety, tolerability, and immunogenicity of an inactivated
- 506 SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised,
- 507 double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis
- 508 [Internet] 2021 [cited 2021 Oct 6];21(2):181–92. Available from:
- 509 https://pubmed.ncbi.nlm.nih.gov/33217362/
- 510 5. SM B, K A, PA G, et al. Safety and Immunogenicity of an Inactivated SARS-
- 511 CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile. Clin Infect Dis
- 512 [Internet] 2021 [cited 2021 Oct 9];Available from:
- 513 https://pubmed.ncbi.nlm.nih.gov/34537835/
- 514 6. Sauré D, O'Ryan M, Torres JP, Zuniga M, Santelices E, Basso LJ. Dynamic
- 515 IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19

- 516 vaccines in Chile: a sentinel surveillance study. Lancet Infect Dis [Internet]
- 517 2021 [cited 2021 Oct 11];0(0). Available from:
- 518 http://www.thelancet.com/article/S1473309921004795/fulltext
- 519 7. Duarte LF, Gálvez NMS, Iturriaga C, et al. Immune Profile and Clinical
- 520 Outcome of Breakthrough Cases After Vaccination With an Inactivated
- 521 SARS-CoV-2 Vaccine. Front Immunol [Internet] 2021 [cited 2021 Oct
- 522 11];0:3884. Available from:
- 523 https://www.frontiersin.org/articles/10.3389/fimmu.2021.742914/full
- 524 8. Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated
- 525 SARS-CoV-2 Vaccine in Chile. https://doi.org/101056/NEJMoa2107715
- 526 [Internet] 2021 [cited 2021 Oct 7];385(10):875–84. Available from:

527 https://www.nejm.org/doi/full/10.1056/NEJMoa2107715

- 528 9. Chile ha administrado más de 41 millones 980 mil dosis de vacuna contra
- 529 SARS-CoV-2 Ministerio de Salud Gobierno de Chile [Internet]. [cited 2021
- 530 Dec 10];Available from: https://www.minsal.cl/chile-ha-administrado-mas-de-
- 531 41-millones-980-mil-dosis-de-vacuna-contra-sars-cov-2/
- 532 10. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are
- 533 highly predictive of immune protection from symptomatic SARS-CoV-2
- 534 infection. Nat Med 2021 277 [Internet] 2021 [cited 2021 Oct 6];27(7):1205–
- 535 11. Available from: https://www.nature.com/articles/s41591-021-01377-8
- 536 11. Protection duration after vaccination or infection Swiss National COVID-19
- 537 Science Task Force [Internet]. [cited 2021 Oct 6]; Available from:
- 538 https://sciencetaskforce.ch/en/policy-brief/protection-duration-after-
- 539 vaccination-or-infection/

540	12.	Pan H, Wu Q, Zeng G, et al. Immunogenicity and safety of a third dose, and
541		immune persistence of CoronaVac vaccine in healthy adults aged 18-59
542		years: interim results from a double-blind, randomized, placebo-controlled
543		phase 2 clinical trial. medRxiv [Internet] 2021 [cited 2021 Oct
544		6];2021.07.23.21261026. Available from:
545		https://www.medrxiv.org/content/10.1101/2021.07.23.21261026v1
546	13.	Cao Y, Yisimayi A, Bai Y, et al. Humoral immune response to circulating
547		SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. Cell
548		Res 2021 317 [Internet] 2021 [cited 2021 Oct 8];31(7):732–41. Available
549		from: https://www.nature.com/articles/s41422-021-00514-9
550	14.	Melo-González F, Soto JA, González LA, et al. Recognition of Variants of
551		Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated
552		Vaccine. Front Immunol [Internet] 2021;12. Available from:
553		https://www.frontiersin.org/articles/10.3389/fimmu.2021.747830/full
554	15.	Clemens SAC, Weckx L, Clemens R, et al. Heterologous versus homologous
555		COVID-19 booster vaccination in previous recipients of two doses of
556		CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-
557		inferiority, single blind, randomised study. Lancet [Internet] 2022 [cited 2022
558		Jan 24];0(0). Available from:
559		http://www.thelancet.com/article/S0140673622000940/fulltext
560	16.	Pérez-Then E, Lucas C, Monteiro VS, et al. Neutralizing antibodies against
561		the SARS-CoV-2 Delta and Omicron variants following heterologous
562		CoronaVac plus BNT162b2 booster vaccination. Nat Med 2022 [Internet]
563		2022 [cited 2022 Jan 24];1–1. Available from:

564		https://www.nature.com/articles/s41591-022-01705-6
565	17.	Acevedo M, Alonso-Palomares L, Pantano S, Pasteur I, Navarrete M, Soto-
566		Rifo R. Neutralization of the emerging SARS-CoV-2 variant Lambda by
567		antibodies elicited by inactivated virus and mRNA vaccines. 2021 [cited 2022
568		Jan 31];Available from: https://www.researchsquare.com
569	18.	Depto Inmunizaciones D, De Prevención D, Control, Y Enfermedades S,
570		Pública M de salud. DOSIS DE REFUERZO EN LA CAMPAÑA DE
571		VACUNACIÓN CONTRA SARS-COV-2 EN CHILE. 2021 [cited 2021 Oct
572		6];Available from: https://www.minsal.cl/wp-
573	19.	Immunization Campaign against SARS-CoV-2 Early estimates of the
574		effectiveness of booster shots in Chile [Internet]. 2021 [cited 2021 Dec
575		10];Available from: https://www.minsal.cl/wp-content/uploads/2021/10/2021-
576		10-07-EFECTIVIDAD-DOSIS-DE-REFUERZO_ENG.pdf
577	20.	World medical association. World Medical Association declaration of
578		Helsinki: Ethical principles for medical research involving human subjects
579		[Internet]. JAMA - J. Am. Med. Assoc. 2013 [cited 2021 Oct 6];310(20):2191-
580		4. Available from: https://pubmed.ncbi.nlm.nih.gov/24141714/
581	21.	WHO/BS.2020.2403 Establishment of the WHO International Standard and
582		Reference Panel for anti-SARS-CoV-2 antibody [Internet]. [cited 2021 Oct
583		8];Available from: https://www.who.int/publications/m/item/WHO-BS-
584		2020.2403
585	22.	Acevedo ML, Alonso-Palomares L, Bustamante A, et al. Infectivity and
586		immune escape of the new SARS-CoV-2 variant of interest Lambda.
587		medRxiv [Internet] 2021 [cited 2022 Jan 24];2021.06.28.21259673. Available

588		from: https://www.medrxiv.org/content/10.1101/2021.06.28.21259673v1
589	23.	Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to
590		SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and
591		Unexposed Individuals. Cell 2020;181(7):1489-1501.e15.
592	24.	Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence
593		of SARS-CoV-2 Infection in Health Care Workers.
594		https://doi.org/101056/NEJMoa2034545 [Internet] 2020 [cited 2021 Oct
595		8];384(6):533–40. Available from:
596		https://www.nejm.org/doi/10.1056/NEJMoa2034545
597	25.	Sabino EC, Buss LF, Carvalho MPS, et al. Resurgence of COVID-19 in
598		Manaus, Brazil, despite high seroprevalence. Lancet 2021;397(10273):452-
599		5.
600	26.	Wang K, Cao Y, Zhou Y, et al. A third dose of inactivated vaccine augments
601		the potency, breadth, and duration of anamnestic responses against SARS-
602		CoV-2. medRxiv [Internet] 2021 [cited 2021 Oct 8];2021.09.02.21261735.
603		Available from:
604		https://www.medrxiv.org/content/10.1101/2021.09.02.21261735v1
605	27.	Bar-On YM, Goldberg Y, Mandel M, et al. BNT162b2 vaccine booster dose
606		protection: A nationwide study from Israel. medRxiv [Internet] 2021 [cited
607		2021 Oct 8];2021.08.27.21262679. Available from:
608		https://www.medrxiv.org/content/10.1101/2021.08.27.21262679v1
609	28.	Seyahi E, Bakhdiyarli G, Oztas M, et al. Antibody response to inactivated
610		COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled
611		study among hospital workers and elderly. Rheumatol Int 2021 418 [Internet]

- 612 2021 [cited 2021 Oct 8];41(8):1429–40. Available from:
- 613 https://link.springer.com/article/10.1007/s00296-021-04910-7
- 614 29. Widge AT, Rouphael NG, Jackson LA, et al. Durability of Responses after
- 615 SARS-CoV-2 mRNA-1273 Vaccination.
- 616 https://doi.org/101056/NEJMc2032195 [Internet] 2020 [cited 2021 Oct
- 617 8];384(1):80–2. Available from:
- 618 https://www.nejm.org/doi/full/10.1056/NEJMc2032195
- 619 30. Li M, Yang J, Wang L, et al. A booster dose is immunogenic and will be
- 620 needed for older adults who have completed two doses vaccination with
- 621 CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2
- 622 clinical trial. medRxiv [Internet] 2021 [cited 2021 Oct
- 623 8];2021.08.03.21261544. Available from:
- 624 https://www.medrxiv.org/content/10.1101/2021.08.03.21261544v1
- 625 31. Mateus J, Dan JM, Zhang Z, et al. Low-dose mRNA-1273 COVID-19 vaccine
- 626 generates durable memory enhanced by cross-reactive T cells. Science (80-
- 627) [Internet] 2021 [cited 2021 Nov 11];374(6566). Available from:
- 628 https://www.science.org/doi/abs/10.1126/science.abj9853
- 629 32. Guerrera G, Picozza M, D'Orso S, et al. BNT162b2 vaccination induces
- 630 durable SARS-CoV-2 specific T cells with a stem cell memory phenotype.
- 631 Sci Immunol [Internet] 2021 [cited 2021 Nov 11];Available from:
- 632 https://www.science.org/doi/abs/10.1126/sciimmunol.abl5344
- 633 33. Cao Y, Hao X, Wang X, et al. Humoral immunogenicity and reactogenicity of
- 634 CoronaVac or ZF2001 booster after two doses of inactivated vaccine. Cell
- 635 Res 2021 [Internet] 2021 [cited 2021 Dec 10];1–3. Available from:

636		https://www.nature.com/articles/s41422-021-00596-5
637	34.	Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the
638		SARS-CoV-2 Omicron variant in southern Africa. Nat 2022 [Internet] 2022
639		[cited 2022 Jan 31];1–10. Available from:
640		https://www.nature.com/articles/s41586-022-04411-y
641	35.	Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly
642		resistant against antibody-mediated neutralization: Implications for control of
643		the COVID-19 pandemic. Cell [Internet] 2021 [cited 2022 Jan 25];Available
644		from: https://linkinghub.elsevier.com/retrieve/pii/S0092867421014951
645	36.	Ai J, Zhang H, Zhang Q, et al. Recombinant protein subunit vaccine booster
646		following two-dose inactivated vaccines dramatically enhanced anti-RBD
647		responses and neutralizing titers against SARS-CoV-2 and Variants of
648		Concern. Cell Res 2021 [Internet] 2021 [cited 2021 Dec 10];1-4. Available
649		from: https://www.nature.com/articles/s41422-021-00590-x
650	37.	A T, J S, N M, et al. Impact of SARS-CoV-2 variants on the total CD4 + and
651		CD8 + T cell reactivity in infected or vaccinated individuals. Cell reports Med
652		[Internet] 2021 [cited 2021 Oct 25];2(7). Available from:
653		https://pubmed.ncbi.nlm.nih.gov/34230917/
654	38.	Gao Y, Cai C, Grifoni A, et al. Ancestral SARS-CoV-2-specific T cells cross-
655		recognize the Omicron variant. Nat Med 2022 [Internet] 2022 [cited 2022 Jan
656		25];1–9. Available from: https://www.nature.com/articles/s41591-022-01700-
657		x
658		
659		

660 Figures legends

661

662 Figure 1: Study profile, enrolled volunteers, and cohort included in the study by November 11th. 2021. A. From the one hundred and eighty-six vaccinated 663 664 individuals that received the booster dose, seventy-seven volunteers that received two doses of CoronaVac® in a 28 days interval (0-28 days schedule of 665 666 vaccination), were selected from the center assigned for the immunogenicity study. Seventy-seven volunteers were tested for neutralizing antibodies by sVNT, sixty-667 two were selected to analyze neutralizing antibodies by cVNT and forty were 668 669 selected to analyze cellular immunity. Analyses for immunity against SARS-CoV-2 670 variants were performed in 30 volunteers for sVNT, pVNT and T cells assays. B. Timeline of 0-28 days schedule of vaccination and booster dose immunization. 671 672 Text in red denotes timepoints at which blood draws occurred.

673

Figure 2: Quantification of circulating antibodies inhibiting the interaction 674 675 between the S1-RBD and hACE2 and in live SARS-CoV-2 in volunteers that 676 received the booster dose of CoronaVac®. A-C. Inhibiting antibodies were 677 detected in serum of volunteers immunized with CoronaVac® using a surrogate 678 Viral Neutralization Test (sVNT), which quantifies the interaction between S1-RBD 679 and hACE2 on ELISA plates. Results were obtained from a total of seventy-seven 680 volunteers (A), thirty-six of them were adults between 18-59 years old (B), and 681 forty-one of them were \geq 60 years old (C). Data is represented as WHO arbitrary 682 units/mL, the numbers above each set of individual data points show the 683 Geometric Mean Units (GMU), the error bars indicate the 95% CI, and the number

684 at the right represents the fold increase of the GMU four weeks after the third dose as compared with the respective times after administration of the second dose. D-685 686 F. Neutralizing antibodies were detected in serum of volunteers that received a booster dose of CoronaVac® twenty weeks after the second dose, using a 687 688 conventional Viral Neutralization Test (cVNT), which quantifies the reduction of 689 cytopathic effect (CPE) in Vero E6 cells infected with SARS-CoV-2. Results were obtained from 62 volunteers (D), 30 of them were adults between 18-59 years old 690 691 (E), and 32 of them were \geq 60 years old (F). Data are expressed as the reciprocal 692 of the highest serum dilution preventing 100% cytopathic effect, the numbers 693 above each set of individual data points show the Geometric Mean Titer (GMT). 694 the error bars indicate the 95% CI, and the number at the right represents the fold increase of the GMU the third dose + 4 weeks as compared with the respective 695 696 times after administration of the second dose. CI were not adjusted for multiplicity 697 and should not be used for inference. A repeated measures One-Way ANOVA test assessed statistical differences to compare all times against 3rd dose + four weeks. 698 699 ****p<0.0001.

700

Figure 3: Changes in activation-induced markers (AIMs) expression in CD4⁺ T
cells and in the number of IFN-γ-secreting cells specific for SARS-CoV-2 after
a booster dose of CoronaVac[®]. A-C. AIM⁺ CD4⁺ T cells were quantified in
peripheral blood mononuclear cells of volunteers that received a booster dose of
CoronaVac[®] twenty weeks after the second dose by flow cytometry, upon
stimulation with mega-pools of peptides derived from SARS-CoV-2 proteins. The

707 percentage of activated AIM⁺ CD4⁺ T cells (OX40⁺, CD137⁺) were determined upon 708 stimulation for 24h with MP-S+R in samples obtained at pre-immune, two weeks 709 after the second dose, four weeks after the second dose, twenty weeks the second 710 dose, and four weeks after the booster dose. Data from flow cytometry was 711 normalized against DMSO and analyzed separately by a Friedman test against the 712 booster dose. Results were obtained from a total of forty volunteers (A), twenty-713 one were of them were adults between 18-59 years old (B), and nineteen of them 714 were \geq 60 years old (**C**). Changes in the secretion of IFN- γ were quantified as the 715 number of Spot Forming Cells (SFCs) in peripheral blood mononuclear cells of 716 volunteers that received a booster dose of CoronaVac® 20 weeks after the second 717 dose. **D-F**. Data was obtained upon stimulation with MP-S+R for 48h in samples 718 obtained at pre-immune, two weeks after the second dose, four weeks after the 719 second dose, twenty weeks the second dose, and four weeks after the booster 720 dose. Results were obtained from a total of 40 volunteers (D), 21 were of them 721 were adults between 18-59 years old (E), and 19 of them were \geq 60 years old (F). 722 Data from ELISPOT were analyzed separately by Friedman test against the 723 booster dose *p<0.05; **p<0.005; ***p< < 0.001; ****p<0.0001.

724

Figure 4: Quantification of circulating neutralizing antibodies against SARSCoV-2 variants in volunteers that received the booster dose of CoronaVac®.
A. Neutralizing antibodies were detected in the serum of thirty volunteers, four
weeks after the booster dose of CoronaVac®, using a pseudotyped virus
neutralization test (pVNT). Data are expressed as the reciprocal of the highest

730 dilution preventing 80% of the infection (ID80). Numbers above the bars show the 731 Mean, and the error bars indicate the 95% CI. The number at the right represents 732 the fold decrease of the GMT four weeks after the booster dose as compared with 733 the response of D614G **B**. Seropositivity rate of neutralizing antibodies is shown for 734 each time point analyzed. Numbers above the bars show the percentage of 735 seropositivity rate in the respective graphs. Numbers above the bars show the 736 percentage of seropositivity rate in the respective graphs. A repeated measures 737 One-Way ANOVA test assessed statistical differences of the GMT to compare 738 each variant against D614G. *p<0.05; ***p < 0.001; ****p<0.0001

- 739
- 740

Figure 5: A booster dose of CoronaVac[®] induce changes in the number of 741 742 IFN-γ-secreting cells and in activation-induced markers (AIMs) expression in 743 CD4⁺ T cells specific for the Spike protein of SARS-CoV-2 variants. A. 744 Changes in the secretion of IFN- γ , determined as the number of Spot Forming 745 Cells (SFCs) were determined. Data was obtained upon stimulation of PBMC with 746 MP-S of variant of concern of SARS-CoV-2 for 48h in samples obtained four weeks 747 after the booster dose. Data shown represent mean + 95%Cl. Data from thirty 748 volunteers were analyzed at four weeks after the booster dose to compare among 749 the MP-S of the variant of concern. Data from ELISPOT were analyzed separately 750 by Friedman test against the WT MP-S. No significant differences were obtained. 751 **B**. AIM⁺ CD4⁺ T cells were quantified in peripheral blood mononuclear cells of thirty 752 volunteers four weeks after that received a booster dose of CoronaVac® by flow

cytometry, upon stimulation with mega-pools of peptides derived from proteins of variant of concern of SARS-CoV-2. The percentage of activated AIM⁺ CD4⁺ T cells (OX40⁺, CD137⁺) were determined upon stimulation for 24h with MP-S+R in samples obtained four weeks after the booster dose. Data shown represent mean + 95%CI. Data from flow cytometry was normalized against DMSO. No significant differences were obtained between WT and the variant MP stimulation.

759

Table 760

761 Table 1: Demographic and clinical data of seventy-seven volunteers analyzed. 762

763

764

	Age group	AHT N (%)	AR N (%)	MD N (%)	Obesity N (%)	Insulin resistance N (%)	COPD N (%)	HT N (%)
Female sex N (%)	41 (53.2)	11 (14.3)	8 (10.4)	1 (1.3)	6 (7.8)	6 (7.8)	3 (3.9)	7 (9.1)
18-59 years old	18 (23.4)	3 (3.9)	6 (7.8)	0	2 (2.6)	3 (3.9)	0	2 (2.6)
≥60 years old	23 (30.0)	8 (10.4)	2 (2.6)	1 (1.3)	4 (5.2)	3 (3.9)	3 (3.9)	5 (6.5)
Male sex N (%)	36 (46.8)	11 (14.3)	8 (10.4)	3 (3.9)	11 (14.3)	1 (1.3)	0	1 (1.3)
18-59 years old	17 (22.0)	4 (5.2)	4 (5.2)	2 (2.6)	4 (5.2)	0	0	0
≥60 years old	19 (24.6)	7 (9.1)	4 (5.2)	1 (1.3)	7 (9.1)	1 (1.3)	0	1 (1.3)

765 Arterial hypertension: AHT; Chronic obstructive pulmonary disease: COPD; Mellitus diabetes: MD; 766 767 Hypothyroidism: HT; Allergic rhinitis: AR

768 Table 2: Seropositivity rates, Geometric Mean Titer (GMT), and Geometric

Mean Units (GMU) of circulating neutralizing antibodies against SARS-CoV-2
 RBD.

	٨٥٥		2 nd dose	2 nd dose	2 nd dose	3 rd dose
Methodology	aroup	Indicators	+ 2	+ 4	+ 20	+ 4
	group		weeks	weeks	weeks	weeks
		Seropositivity n/N	72/77	73/77	38/77	75/77
		(%)	93.5	94.8	49.4	97.4
	Total	GMU	168.0	124.8	39.0	499.4
	Vaccine	95% CI	126.8- 222.5	96.3- 161.7	32.4-47.0	370.6- 673.0
		GMT	25.8	16.6	3.5	53.0
		95% CI	19.5-34.2	13.1-21.0	3.0-4.1	40.8-68.8
		Seropositivity n/N	35/36	36/36	24/36	36/36
		(%)	97.2	97.2	66.7	100
	10 50	GMU	220.2	155.0	48.9	918.8
SVNI	18-59	95% CI	150.7- 321.7	108.0- 222.6	37.6-63.5	623.4- 1354
		GMT	33.3	19.1	4.3	82.8
		95% CI	23.4-47.3	14.0-26.1	3.4-5.4	59.7- 114.8
	≥60	Seropositivity n/N	38/41	39/42	15/42	40/42
		(%)	90.5	92.9	35.7	95.2
		GMU	134.1	104.1	32.4	300.5
		95% CI	89.2- 201.6	71.8- 151.0	25.1-41.8	203.5- 443.6
		GMT	20.8	14.7	2.4	36.5
		95% CI	13.6-31.9	10.3-21.0	2.4-3.5	25.3-52.7
		Seropositivity n/N	49/62	51/62	44/62	62/72
	Total Vaccine	(%)	79.0	82.3	71.0	100
		GMT	12.8	13.5	8.3	89.5
cVNT		95% CI	8.8-18.5	9.6-19.2	5.6-12.2	64.0- 125.2
	18-59	Seropositivity n/N	25/30	27/30	23/30	30/30
		(%)	83.3	90.0	76.7	100

		GMT	17.5	18.8	14.2	176.9
		95% CI	9.8-31.3	11.2-31.7	7.1-28.4	111.7- 280.1
		Seropositivity n/N	24/32	24/32	21/32	32/32
	≥60	(%)	75.0	75.0	65.6	100
		GMT	9.5	9.9	5.0	47.3
		95% CI	5.8-15.4	6.2-15.8	3.5-7.0	32.1-69.5

sVNT: Surrogate Virus Neutralization; cVNT: Conventional Virus Neutralization; GMT: Geometric
 mean titer; GMU: Geometric mean units.

773 **Table 3: Seropositivity rates, Geometric Mean Titer (GMT) of circulating** 774 **neutralizing antibodies against SARS-CoV-2 RBD of D614G and variants of**

775 concern (Delta and Omicron).

776

	Variant	D614G	Delta (B.1.617.2)	Omicron (B.1.1.529)
	Indicators	3rd dose + 4 weeks	3rd dose + 4 weeks	3rd dose + 4 weeks
	Seropositivity n/N	30/30	28/30	23/30
pVNT	(%)	100	93.3	76.6
	GMT	241.8	159.2	50.7
	95% CI	155.7- 375.6	99.1-256.0	30.4-84.8

777

778 GMT: Geometric mean titer.

779

780











